Department of Otorhinolaryngology-Head and Neck Surgery, Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.
Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.
Sci Rep. 2023 Jul 31;13(1):12373. doi: 10.1038/s41598-023-39316-x.
Hearing impairment, the third largest health burden worldwide, currently lacks definitive treatments or preventive drugs. This study compared the effects of hydrophilic and lipophilic statin on hearing loss using a common database model. This retrospective multicenter study was conducted in three hospitals in South Korea (Anam, Guro, Ansan). We enrolled patients with hyperlipidemia with an initial hearing loss diagnosis. Data were collected during January 1, 2022-December 31, 2021 using the Observational Health Data Science and Informatics open-source software and Common Data Model database. The primary outcome was the occurrence of first-time hearing loss following a hyperlipidemia diagnosis, as documented in the Common Data Model cohort database. The measures of interest were hearing loss risk between hydrophilic and lipophilic statin use. Variables were compared using propensity score matching, Cox proportional regression, and meta-analysis. Among 37,322 patients with hyperlipidemia, 13,751 (7669 men and 6082 women) and 23,631 (11,390 men and 12,241 women) were treated with hydrophilic and lipophilic statins, respectively. After propensity score matching, according to the Kaplan-Meier curve, hearing loss risk did not significantly differ among the hospitals. The hazard ratio (HR) of the male patients from Anam (0.29, [95% confidence interval (CI), 0.05-1.51]), Guro (HR, 0.56, [95% CI 0.18-1.71]), and Ansan (hazard ratio, 0.29, [95% CI 0.05-1.51]) hospitals were analyzed using Cox proportional regression. Overall effect size (HR, 0.40, [95% CI 0.18-0.91]) was estimated using meta-analysis, which indicated that hearing loss risk among hydrophilic statin users was less than that among lipophilic statin users and was statistically significant. Men in the hydrophilic statin group had a lower risk of hearing impairment than those in the lipophilic statin group.
听力损伤是全球第三大健康负担，但目前尚无明确的治疗方法或预防药物。本研究使用通用数据库模型比较了亲水性和疏水性他汀类药物对听力损失的影响。这项回顾性多中心研究在韩国的三家医院（安岩、九老、安阳）进行。我们招募了患有高血脂症且最初被诊断出听力损失的患者。数据是在 2022 年 1 月 1 日至 2021 年 12 月 31 日期间使用观察性健康数据科学和信息学开源软件和通用数据模型数据库收集的。主要结局是在高血脂症诊断后首次出现听力损失的情况，这在通用数据模型队列数据库中有记录。关注的措施是亲水性和疏水性他汀类药物使用之间的听力损失风险。使用倾向评分匹配、Cox 比例回归和荟萃分析比较变量。在 37322 名患有高血脂症的患者中，分别有 13751 名（7669 名男性和 6082 名女性）和 23631 名（11390 名男性和 12241 名女性）接受了亲水性和疏水性他汀类药物治疗。经过倾向评分匹配后，根据 Kaplan-Meier 曲线，三家医院的听力损失风险没有显著差异。安岩（0.29，[95%置信区间（CI），0.05-1.51]）、九老（HR，0.56，[95%CI 0.18-1.71]）和安阳（危险比，0.29，[95%CI 0.05-1.51]）医院的男性患者使用 Cox 比例回归进行分析。使用荟萃分析估计总体效应大小（HR，0.40，[95%CI 0.18-0.91]），表明亲水性他汀类药物使用者的听力损失风险低于疏水性他汀类药物使用者，且具有统计学意义。亲水性他汀类药物组的男性听力障碍风险低于疏水性他汀类药物组。
